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Abstract
We report here that a simple, well-defined, and easy-to-scale up nanocarrier, PEG5000-lysyl-(α-
Fmoc-ε-t-Boc-lysine)2 conjugate (PEG-Fmoc), provides high loading capacity, excellent
formulation stability and low systemic toxicity for paclitaxel (PTX), a first-line chemotherapeutic
agent for various types of cancers. 9-Fluorenylmethoxycarbonyl (Fmoc) was incorporated into the
nanocarrier as a functional building block to interact with drug molecules. PEG-Fmoc was
synthesized via a three-step synthetic route, and it readily interacted with PTX to form mixed
nanomicelles of small particle size (25–30 nm). The PTX loading capacity was about 36%, which
stands well among the reported micellar systems. PTX entrapment in this micellar system is
achieved largely via an Fmoc/PTX π-π stacking interaction, which was demonstrated by
fluorescence quenching studies and 13C-NMR. PTX formulated in PEG-Fmoc micelles
demonstrated sustained release kinetics, and in vivo distribution study via near infrared
fluorescence imaging demonstrated an effective delivery of Cy5.5-labled PTX to tumor sites. The
maximal tolerated dose for PTX/PEG-Fmoc (MTD > 120 mg PTX/kg) is higher than those for
most reported PTX formulations, and in vivo therapeutic study exhibited a significantly improved
antitumor activity than Taxol, a clinically used formulation of PTX. Our system may hold promise
as a simple, safe, and effective delivery system for PTX with a potential for rapid translation into
clinical study.
© 2014 Elsevier Ltd. All rights reserved.
*Address correspondence to: Song Li, M.D., Ph.D., Center for Pharmacogenetics, University of Pittsburgh School of Pharmacy, 639
Salk Hall, Pittsburgh, PA 15261, Tel: 412-383-7976, Fax: 412-648-1664, sol4@pitt.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Biomaterials. Author manuscript; available in PMC 2015 August 01.
Published in final edited form as:























micelle; 9-Fluorenylmethoxycarbonyl; drug-carrier interaction; paclitaxel; drug delivery; cancer
therapy
1. Introduction
Nanomedicine has been shown to dramatically improve the in vivo performance of various
anticancer agents through modifying their physiochemical properties, pharmacokinetics, and
distribution profiles [1–6]. To date, a variety of polymer- and lipid-based systems have been
developed and a few of them are currently being used in the clinic [7–11]. However, it
remains a challenge to develop a simple, easy-to-scale up system that provides excellent
drug loading capacity and formulation stability.
As a well-developed delivery system, micelles are attractive due to the ease of preparation,
and small sizes that can contribute to a reduced rate of elimination from circulation and
enhanced accumulation at solid tumors with leaky vasculature based on the enhanced
penetration and retention (EPR) effect [12, 13]. Most of the current micellar systems are
composed of two distinct domains, one being hydrophilic and the other hydrophobic, and
drug loading is solely based on the interactions of their hydrophobic domains with the
poorly water-soluble drugs [14–16]. While working well for highly hydrophobic/lipophilic
agents, these systems exhibit limited effectiveness for drugs with moderate hydrophobicity
due to limited drug-carrier compatibility.
Recent studies have highlighted the benefits of introducing other drug-interactive domains
into the conventional micellar systems to improve the drug loading capacity and formulation
stability through introduction of additional mechanisms of carrier/drug interactions. For
example, some studies have demonstrated that inclusion of a hydrotropic domain or entire
drug molecule such as doxorubicin can effectively improve the performance of several
polymeric systems with respect to drug loading capacity and colloidal stability of drug-
loaded micelles [17–21].
We have recently developed a new concept that introduction of a drug-interactive domain at
the interfacial region represents an effective strategy to improve the compatibility between
lipid-core micelles and the hydrophobic drugs. Among several drug-interactive domains
tested, 9-Fluorenylmethoxycarbonyl (Fmoc) was shown to have an unusual propensity in
interacting with many types of agents of diverse structure and water solubility [22]. After
interfacially modified with Fmoc groups, polyethylene glycol (PEG)-lipopeptides are active
in formulating a panel of dissimilar drugs, ranging from paclitaxel (PTX), steroids,
xanthene- and porphyrin-based photodynamic agents, to hydrophobic peptide drugs, with
significant improvements in both drug loading capacity and drug retention [23]. These data
strongly suggest that Fmoc qualifies as a “formulation chemophor”, exhibiting a potent
activity in interacting with various pharmaceutical agents and thus a capability of improving
carrier-drug compatibility.
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In general, it is believed that a large hydrophobic domain such as a lipid chain or
hydrophobic polymer is necessary to construct micelle-forming surfactants, and indeed,
Fmoc-containing PEG-lipid conjugates were more effective than the counterparts without a
lipid motif in formulating a number of hydrophobic agents. Interestingly, a PEG-Fmoc
conjugate without a lipid motif, PEG5000-lysyl-(α-Fmoc-ε-t-Boc-lysine)2 (PEG-Fmoc), was
found to be highly effective in solubilizing PTX. More surprising is the finding that PEG-
Fmoc was significantly more effective than the counterpart with a lipid motif in formulating
PTX. This study is focused on characterization of PEG-Fmoc as a simple and effective
micellar formulation for PTX. The potential mechanism involved in the drug/carrier
interaction between PEG-Fmoc and PTX is also investigated, which may shed insights into
the future development of further improved nanocarrier for therapeutic agents.
2. Materials and methods
2.1. Reagents
Paclitaxel (PTX, >99%) was purchased from TSZ Chem (MA, USA). Docetaxel (DTX,
>99%) was obtained from LC Laboratories (MA, USA). α-Fmoc-ε-Boc-lysine, di-Boc-
lysine, N, N′-dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS),
trifluoroacetic acid (TFA), and triethylamine (TEA) were obtained from Acros Organic (NJ,
USA). Monomethoxy PEG5000, monomethoxy PEG550, cholesterol (CHOL), 4-
dimethylaminopyridine (DMAP), ninhydrin, and other unspecified chemicals were all
purchased from Sigma-Aldrich (MO, USA). Dulbecco’s phosphate buffered saline (DPBS),
Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), 100X penicillin-
streptomycin solution were all purchased from Invitrogen (NY, USA). All solvents used in
this study were HPLC grade.
2.2 Synthesis of PEG5000-lysyl-(α-Fmoc-ε-t-Boc-lysine)2 (PEG-Fmoc)
PEG-Fmoc was synthesized largely following our published method [23]. Briefly, 1 equiv.
of monomethoxy PEG5000 was mixed with excess amount of di-Boc-lysine and DCC in
dichloromethane (DCM) with addition of DMAP, and the reaction was allowed at room
temperature for 48 h. The mixture was filtered and precipitated in ice-cold ether, followed
by washes with cold ethanol and ether to obtain purified PEG5000-di-Boc-lysine. The PEG
derivative was then treated with DCM/TFA (1:1, v/v) for 2 h at room temperature, followed
by removal of the solvent, precipitation in cold ether, and washes with cold ethanol and
ether. Finally, the deprotected PEG5000-lysine-NH2 was mixed with excess amount of α-
Fmoc-ε-Boc-lysine that was pre-activated with NHS, DCC, and small amount of DMAP in
DCM at 37°C for 4 h. The reaction was allowed at 37 °C till the ninhydrin test became
negative, indicating the absence of free amino groups. The reaction mixture was filtered and
precipitated by ice-cold ether, followed by washes with cold ethanol and ether. The obtained
material was dissolved in water and filtered through a 450 nm filter, followed by
lyophilization to yield the powder of purified PEG5000-lysyl-(α-Fmoc-ε-t-Boc-lysine)2.
2.3 Preparation and biophysical characterization of PTX/PEG-Fmoc mixed micelles
Thin-film hydration method was utilized for preparation of PTX/PEG-Fmoc mixed
nanomicelles. PEG-Fmoc and PTX in chloroform were well mixed in a glass tube at
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designated molar ratios. A thin film of carrier/drug mixture was generated through removal
of the organic solvent by a gentle stream of nitrogen. The trace amount of solvent was
further removed via vacuum for 2 h. Then the film was hydrated and suspended in DPBS by
vortex to obtain a clear solution of PTX/PEG-Fmoc mixed nanomicelles. Any non-
entrapped drug was removed by filtration through 450 nm PVDF syringe filter.
The size distribution of PTX/PEG-Fmoc mixed nanomicelles was examined by dynamic
light scattering (DLS), and the zeta potential was measured via a Malvern Zeta Nanosizer.
The morphology was observed by transmission electron microscopy (TEM) after negative
staining. The CMC measurement was performed as reported before with pyrene as a
fluorescence probe [23]. To quantify PTX in the micelles, PTX was extracted by methanol,
and detected by Waters Alliance 2695–2998 high-performance liquid chromatography
(HPLC) system with a RP-18 column (250 mm × 4.6 mm) equipped with a UV detector at
227 nm at room temperature. A mixture of methanol/water (80:20, v/v) was used as mobile
phase at a flow rate at 0.8 mL/min. The drug loading capacity (DLC) and efficiency (DLE)
were calculated using the formula:
2.4 Effect of lyophilization/reconstitution on particle sizes
One mL of PTX/PEG-Fmoc in DPBS was prepared as described above and the PTX
concentration was kept at 1 mg/mL. The clear solution was frozen and lyophilized overnight
to obtain white powder. The powder was then reconstituted with 1 mL of distilled water to
obtain a clear solution. Particle sizes of the PTX-loaded micelles before and after
lyophilization/reconstitution were recorded via DLS using a Zetasizer.
2.5 Differential scanning calorimetry (DSC) analysis
A Mettler Toledo DSC was used for DSC analysis. Samples (PTX, PEG-Fmoc/PTX, and
drug-free PEG-Fmoc) were accurately weighed and placed in aluminum crucibles, which
were sealed using a Mettler Toledo sealer. An empty crucible was used as a reference. The
temperature range was set from 25 °C to 285 °C with a rate at 10 °C/min using nitrogen (50
mL/min) as segment gas.
2.6 Fluorescence quenching
PEG5000-lysyl-(α-Fmoc-ε-oleic acid-lysine)2 (PEG-Fmoc-OA) was synthesized as reported
[23]. PTX/PEG-Fmoc and PTX/PEG-Fmoc-OA mixed micelles of various PTX/carrier
molar ratios were prepared in DPBS as described above, and the molar concentrations of
PEG-Fmoc and PEG-Fmoc-OA carrier were kept constant for comparison. The samples
were placed into a 96-well plate, and examined for the fluorescence intensity at the
excitation wavelength of 270 nm and emission wavelength of 300–460 nm using a Synergy
H1 Hybrid Multi-Mode Microplate Reader.
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2.7 In vitro drug release kinetics
Two mL of PTX/PEG-Fmoc mixed micelles in DPBS (PH = 7.4) (1 mg PTX/mL) was
prepared and placed into a dialysis bag (MWCO 12 kDa, Spectrum Laboratories) that was
incubated in a tank containing 200 mL of DPBS with 0.5% (w/v) Tween 80 under gentle
shaking at 37 °C. At scheduled time points (0, 1, 2, 4, 8, 24, 48, and 72 h), the concentration
of PTX remaining in the dialysis bag was measured by HPLC as described above. Taxol
formulation (6 mg PTX/mL in Cremophor EL/ethanol, 1:1, v/v) was diluted with DPBS to a
final PTX concentration of 1 mg/mL and utilized as a control.
2.8 Cell culture
4T1-2 is a mouse metastatic breast cancer cell line. PC-3 and DU145 are two androgen-
independent human prostate cancer cell lines. They were all cultured at 37 °C in DMEM
containing 10% FBS and 1% penicillin-streptomycin in a humidified environment with 5%
CO2.
2.9 In vitro cytotoxicity study
Mouse metastatic breast cancer cell line 4T1.2, and two human prostate cancer cell lines
PC-3 and DU145 were utilized to evaluate the in vitro cytotoxicity of PTX/PEG-Fmoc.
Cells were seeded in 96-well plates at 1000 (4T1.2), 2000 (DU145) and 3000 (PC-3) cells
per well. Twenty-four h later, cells were treated with PTX/PEG-Fmoc or Taxol with PTX
concentrations ranging from 6.25 to 200 ng/mL. Seventy-two h later, 20 μL of 3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT, 5 mg/mL) was added into
each well. Following incubation for 4 h, the medium was removed and 150 μL of DMSO
was added to each well to solubilize the formazan crystal. The absorbance of each well was
detected at 550 nm with a reference wavelength at 630 nm using a microplate reader, and
cell viability was calculated based on the formula below. Untreated cells were included as a
control.
2.10 Animals
Female BALB/c mice (6 to 8 weeks) were purchased from Charles River (Davis, CA), and
male nude mice (6 to 8 weeks) were purchased from Harlan (Livermore, CA). All animals
were housed under pathogen-free conditions according to AAALAC guidelines. All animal-
related experiments were performed in full compliance with institutional guidelines and
approved by the Animal Use and Care Administrative Advisory Committee at the University
of Pittsburgh.
2.11 Maximum tolerated dose (MTD) study
BALB/c mice were randomly divided into seven groups (n=4) and i.v. administered with
PTX/PEG-Fmoc (30, 50, 75, 100, and 120 mg PTX/kg) or Taxol (15, 20, and 25 mg PTX/
kg). Mice were then followed for 10 days for survival and changes in body weight. The
MTD was determined at a maximal dose of PTX that leads to neither animal death nor
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significant changes in the general appearance or greater than 15% of body weight loss over
the entire experimental period.
2.12 Fluorescence optical imaging
Near infrared (NIR) fluorescence imaging was performed to investigate the in vivo
biodistribution of PTX/PEG-Fmoc mixed nanomicelles using PTX labeled with Cy5.5, a
near infrared fluorescence dye. Two hundred μL of PTX-Cy5.5/PEG-Fmoc mixed
nanomicelles (0.2 PTX-Cy5.5 mg/mL) were i.v. injected into SCID mice bearing PC-3
xenografts. At scheduled time points, the mice were anesthetized and scanned with a
Carestream Molecular Imaging’s In-Vivo Imaging FX Pro, using a 60 sec exposure time
with the excitation at 630 nm and the emission at 700 nm. At the end of the imaging study,
all the mice were sacrificed and the major organs and tumors were excised for ex vivo
imaging.
2.13 In vivo therapeutic efficacy
A syngeneic mouse breast cancer model (4T1.2) was established via s.c. inoculation of 2
×105 of 4T1.2 cells into the right flank of female BALB/c mice, and the treatments were
initiated when the tumor size reached ~ 50 mm3. Mice were divided randomly into five
groups (n=5) and received i.v. injection of saline, Taxol (10 mg PTX/kg), and PTX/PEG-
Fmoc (10, 20, and 40 mg PTX/kg), respectively. Tumor volumes were measured by a
caliper and calculated based on the formula: , where L is the longest and W is
the shortest tumor diameters (mm). The data were presented as relative tumor volume (RTV,
the tumor volume at a given time point divided by the tumor volume prior to first treatment).
Mice were sacrificed when tumors developed ulceration. Changes in body weights of all
mice were also monitored during the entire course of treatment to evaluate the potential
toxicity of the formulations. Tumors were harvested at the completion of the experiment and
tumor weights were measured. Tumor growth inhibition rate (IR) was calculated as: 1−
(mean tumor weight of PTX treated group/mean tumor weight of saline treated group) *
100%.
2.14 Statistical analysis
Statistical analysis was performed with two-tailed Student’s t-test between two groups. p <
0.05 was considered statistically significant, and p < 0.01 was considered highly statistically
significant. One-way ANOVA was conducted to assess significance among multiple groups,
followed by two-tailed Student’s t-test if p < 0.05.
3. Results and discussion
3.1 Design, preparation, and characterization of PEG-Fmoc/PTX mixed micelles
We previously developed a new lipid surfactant, PEG5000-lysyl-(α-Fmoc-ε-oleic acid-
lysine)2 (PEG-Fmoc-OA), and examined its utility in formulating a number of therapeutic
agents of diverse structure including PTX [23]. Our data showed that PEG-Fmoc-OA was
much more effective than the counterpart without Fmoc motifs (PEG5000-di-oleoyl lysine,
PEG-OA) with respect to both drug loading capacity and formulation stability. However,
little was known about the molecular basis of carrier-drug interaction for our new micellar
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system. Particularly, a mode of interaction between Fmoc/PTX and its contribution to the
overall performance of the new lipidic vector is largely unknown.
To clearly address this issue, we have synthesized a PEG-Fmoc conjugate without OA
motifs to rule out any influence from lipid motifs whose interaction with drug also
contributes to the overall performance of the new lipidic surfactant. PEG-Fmoc was readily
synthesized via three steps as depicted in Fig. 1A. 1H-NMR spectrum of PEG-Fmoc shows
signals at 3.63 ppm attributed to the methylene protons of PEG backbone, the multiple Fmoc
proton signals between 7.3–7.8 ppm, and the t-Boc signals at 1.44 ppm (Fig. S1). The
molecular weight from MALDI-TOF MS is similar to the theoretical value (6030) (Fig. S2),
indicating the successful synthesis of PEG-Fmoc conjugate.
PEG-Fmoc readily formed small-sized (25~30 nm) micelles in aqueous solution. Negative-
staining EM showed homogeneously distributed spherical particles (Fig. S3). This is
different from PEG-Fmoc-OA that showed tubular morphology on EM, suggesting
formation of filamentous micelles. PEG-OA was known to form spherical micelles [23].
Taken together, these data suggest that both Fmoc and lipid motifs contribute to the
formation of the unique filamentous structure of PEG-Fmoc-OA.
PEG-Fmoc readily formed mixed micelles with PTX and loading of PTX had minimal effect
on the size of the particles as determined by DLS (Fig. 2A). The small size and
homogeneous distribution of the particles were further confirmed by negative-staining TEM
as shown in Fig. 2B. Fig. 2C shows that the CMC value of PEG-Fmoc conjugate was 0.996
μmol/L. And 1H-NMR spectrum analysis showed that the signals from both PEG-Fmoc and
PTX were clearly detected when they were mixed in CDCl3 (Fig. 3A). In contrast, all of the
proton signals of Fmoc and PTX were drastically suppressed in deuterated water, indicating
a complete encapsulation of PTX inside the core area of the self-assembled particles in
aqueous solution (Fig. 3B).
Table 1 shows the drug loading capacity (DLC) at various PEG-Fmoc/PTX molar ratios.
PEG-Fmoc/PTX mixed micelles could be prepared at a carrier/drug molar ratio as low as
0.25/1. At this ratio, the PTX loading capacity was ~36%, which stands well among the
reported PTX micellar formulations. Increasing the carrier/drug ratio was associated with an
increase in drug loading efficiency (DLE) and an improvement in the colloidal stability of
the mixed micelles in 50% FBS/PBS. Surprisingly, PEG-Fmoc was significantly more active
than PEG-Fmoc-OA that has a highest PTX loading capacity of 15.2% [23]. This is in
contrast to solubilization and loading of several other drugs for which PEG-Fmoc-OA was
more active than PEG-Fmoc.
3.2 Mechanism of carrier/drug interactions
Fmoc is known to have strong π-π stacking interaction with other molecules bearing
aromatic rings [24–26], which is normally stronger than the van der Waals interaction. Fmoc
is likely to promote the formation of stable PEG-Fmoc micelles through the Fmoc/Fmoc
interaction. The fact that PTX could be loaded into PEG-Fmoc micelles at a high loading
capacity suggests that Fmoc effectively interacts with PTX. An absence of PTX endothermic
melting peak in PEG-Fmoc/PTX micelles was observed in differential scanning calorimetry
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(DSC) analysis, which indicated a loss of PTX crystallinity caused by a strong carrier-PTX
interaction in PEG-Fmoc/PTX micelles (Fig. 4). To further gain insight into the mechanism
of drug-carrier interaction, fluorescence quenching study was conducted. As depicted in Fig.
5A, a fluorescence maxima of PEG-Fmoc alone was recorded at 305 nm at an excitation
wavelength of 270 nm. However, a dramatic fluorescence quenching was observed when
PTX was loaded into the micelles, and the extent of decrease in fluorescence intensity was
correlated to the amount of PTX loaded in micelles. This fluorescence quenching in the
presence of PTX is likely due to the energy transfer caused by the intermolecular π-π
stacking interaction [27] between Fmoc motifs and the aromatic rings of PTX, which may
represent the major mechanism of carrier/drug interaction in PEG-Fmoc/PTX (Fig. 1B). As
a control, PTX alone did not show any fluorescence at the wavelength range examined.
To further demonstrate that π-π stacking plays a key role in the Fmoc/PTX interaction, the
fluorescence quenching study was similarly conducted with two other hydrophobic
molecules, DTX and CHOL (Fig. S4). As depicted in Fig. S5, DTX, an analog of PTX with
one fewer aromatic ring, caused slightly less fluorescence quenching, which may be due to a
relatively weaker π-π stacking interaction between DTX and Fmoc. In addition, no
significant fluorescence quenching was observed in the hydrophobic interaction between
PEG-Fmoc and CHOL, a highly hydrophobic molecule that does not bear aromatic rings.
Taking together, these data suggest π-π stacking as a major mechanism in the PTX/Fmoc
interaction. However, hydrophobic interaction and hydrogen bonding may also contribute to
the overall interaction between Fmoc and PTX.
Interestingly, PEG-Fmoc-OA exhibited remarkably reduced fluorescence intensity
compared to its lipid-free counterpart, PEG-Fmoc, on equal molar basis (Fig. 5B). This
severe self-quenching is likely due to the extremely strong carrier-carrier π-π interaction.
Incorporation of lipid chains brought changes to packing parameter and molecular
arrangement of PEG-Fmoc-OA assemblies. Unlike PEG-Fmoc that forms spherical micelles,
PEG-Fmoc-OA forms filamentous micelles of tubular structures [23]. This morphology
alteration may facilitate an overwhelming Fmoc/Fmoc interaction between carriers, leading
to an impaired π-π interaction between Fmoc and PTX. Loading of PTX into PEG-Fmoc-
OA micelles may be largely mediated by hydrophobic/hydrophobic interaction. This is in
agreement with the finding that loading of PTX into PEG-Fmoc-OA micelles is not
associated with dramatic quenching of Fmoc fluorescence. The different modes of drug/
carrier interactions might play a major role in the drastic difference in PTX loading capacity
between the two systems (PEG-Fmoc vs PEG-Fmoc-OA).
We further studied the Fmoc/PTX interaction via NMR. Shifts in 13C-NMR spectra of PTX
were recorded in the presence of varying concentrations of PEG-Fmoc. As shown in Fig. 6,
PEG-Fmoc caused significant signal shifts in all of the three aromatic rings of PTX, and
these signal shifts occurred in an Fmoc concentration-dependent manner. It was also
apparent that more dramatic shifts were observed in rings A and B than in ring C as
indicated by the average shift index △ that represents the average absolute value of the
signal shifts of all the six carbon atoms in one aromatic ring. In general, a signal shift of
greater than 0.02 in 13C-NMR spectrum is believed to be significant and suggestive of
intermolecular interaction. These data suggest a strong interaction between Fmoc and the
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aromatic rings of PTX, particularly rings A and B. A stronger interaction between Fmoc and
rings A and B of PTX may be attributed to a higher flexibility of the two rings and a less
steric hindrance imposed by the bulky core of PTX. The interaction of Fmoc with PTX was
similarly demonstrated by NMR with a more simplified system, Fmoc-Lys (Boc)-OH as
shown in Fig. S6. The above data shed some insight into the molecular interaction of PEG-
Fmoc with PTX. However, more studies are needed to better understand the mechanism
involved in the drastic difference between PEG-Fmoc-OA and PEG-Fmoc with respect to
PTX loading capacity.
3.3 Effect of lyophilization/reconstitution on PEG-Fmoc/PTX mixed micelles
The preliminary data suggest that PEG-Fmoc may represent as a simple and effective
micellar system for delivery of PTX. Therefore, we went on to further characterize PEG-
Fmoc/PTX mixed micelles with respect to their biophysical and biological properties. We
first examined the effect of freezing and lyophilization on PEG-Fmoc/PTX mixed micelles
since lyophilization is an important procedure for long-term storage in clinical practice. Our
results showed that PEG-Fmoc/PTX mixed micelles could be lyophilized and then readily
reconstituted in water without any addition of cryo-protectants. In addition, there were no
major changes in size distribution following lyophilization and reconstitution (Fig. 7). This
property may help to facilitate the clinical investigation of this simple delivery system.
3.4 Release kinetics of PTX from PEG-Fmoc/PTX mixed micelles
As an important indicator of formulation stability, release kinetics of PTX from PEG-
Fmoc/PTX was evaluated via a dialysis method, and Taxol, a clinically used PTX
formulation [28, 29] was employed as a comparison. As depicted in Fig. 8, PEG-Fmoc/PTX
mixed micelles exhibited a sustained release profile in PBS, pH 7.4 at 37 °C. After first 24
h, only 19.3% of entrapped PTX was released from PEG-Fmoc/PTX mixed micelles. Even
after 72 h, only 23.5% of PTX was released from PEG-Fmoc/PTX mixed micelles. This
compared favorably to Taxol formulation in which 40.4% of PTX was released during the
1st 24 h. The slow kinetics of PTX release is likely due to a strong carrier/drug interaction,
which may help to facilitate the PTX delivery through minimizing its premature release
from PEG-Fmoc/PTX mixed micelles before they reach the tumor site.
3.5 In vitro cytotoxicity of PEG-Fmoc/PTX
In vitro cytotoxicity of PEG-Fmoc/PTX was evaluated with several tumor cell lines
including mouse metastatic breast cancer cell line, 4T1.2, and two human prostate cancer
cell lines, PC-3 and DU145. As shown in Fig. 9, PEG-Fmoc/PTX mixed micelles exhibited
more potent cytotoxicity than Taxol in all the 3 cancer cell lines tested. The carrier alone did
not show any significant toxicity to cells under the concentrations tested. This increased
cytotoxicity may be attributed to a facilitated entry of PTX into tumor cells. It has been
reported that nano-scale delivery systems enter cells through endocytosis [30–32]. This
could help to bypass the efflux mediated by drug transporters such as P-glycoprotein,
resulting in increased intracellular drug accumulation and improved cytotoxicity.
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3.6 Biodistribution of PEG-Fmoc/PTX micelles through NIR fluorescent optical imaging
To investigate the in vivo fate of PEG-Fmoc/PTX, NIR fluorescence imaging was utilized to
track the biodistribution of PTX in tumor-bearing mice after i.v. injection of PEG-Fmoc/
PTX. Cy5.5, a near infrared fluorescent probe, was conjugated to PTX and SCID mice
bearing human prostate cancer PC-3 xenografts were used. As shown in Fig. 10, Cy5.5-PTX
was largely found at tumor sites 24 h after i.v. administration of PEG-Fmoc/Cy5.5-PTX and
substantial amounts of signal remained at tumor sites even 96 h later. Intravenous
administration of free Cy5.5-PTX led to accumulation of the signals largely at the site of
kidneys (data not shown). This is largely due to the increased hydrophilicity of PTX
following conjugation with Cy5.5, which led to its clearance from the kidneys. After
completion of the whole body imaging study at 96 h post-injection, major organs and tumors
were excised, and ex vivo imaging was performed. Strong NIR fluorescence signals of
Cy5.5-PTX were found in tumor tissues. Moderate levels of signals were also found in lung
and liver, which was due to the nonspecific uptake of nanoparticles by these organs, albeit at
relatively low levels [33]. We also noticed significant levels of NIR signals in kidneys,
which might be due to the clearance of the Cy5.5-PTX that became dissociated from PEG-
Fmoc/Cy5.5-PTX mixed micelles. Very low NIR levels were found in heart and muscle. It
should be noted that coupling of Cy5.5 to PTX led to significant changes in the overall size
and other biophysical properties of PTX as reflected by both reduced loading capacity and
slightly increased sizes for PEG-Fmoc/Cy5.5-PTX mixed micelles (data not shown). Thus,
the targeting efficiency of PEG-Fmoc/PTX might be underestimated with the Cy5.5-PTX-
based NIR imaging. The PK/PD study is currently ongoing to directly examine the
distribution of PTX in tumors and other major organs/tissues. As a control, Cy5.5-PTX
formulated in Cremophor EL yielded poor imaging of the tumor-bearing mice (Fig. S7).
3.7 Maximum tolerated dose (MTD) study
The maximum tolerated dose (MTD) of PEG-Fmoc/PTX was examined in tumor-free mice
and compared to Taxol formulation. Five different doses of PEG-Fmoc/PTX and three doses
of Taxol were tested in BALB/c mice through i.v. injection, followed by monitoring of body
weight and other signs of toxicity of these animals. As shown in Table 2, Taxol could be
tolerated at a maximum PTX dosage of 20 mg/kg. At this dose, no animal death occurred
although several abnormal signs such as convulsion and retarded motion were noticed in
most of the treated mice immediately after injection. Compared with Taxol, PEG-Fmoc/PTX
exhibited a significantly improved safety profile. Even at a dosage as high as 120 mg
PTX/kg (6-fold higher than the MTD of Taxol), neither animal death nor significant weight
loss was observed over the entire experiment period. The high MTD of PEG-Fmoc/PTX
compares favorably to most of the reported PTX micellar formulations, and is consistent
with its excellent formulation stability, slow release profile, and less tendency to accumulate
in major organs as illustrated above, which shall provide a much broader therapeutic dosage
window for enhanced therapeutic efficacy.
3.8 In vivo therapeutic efficacy of PEG-Fmoc/PTX
The in vivo therapeutic efficacy of PEG-Fmoc/PTX was examined in a syngeneic mouse
breast cancer model (4T1.2). 4T1.2 is known as a highly metastatic cancer cell line, and as
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demonstrated in Fig. 11A, rapid tumor growth was observed in saline-treated group. Taxol
showed a modest effect in inhibiting the tumor growth at a PTX dose of 10 mg/kg. At the
same dosage, PEG-Fmoc/PTX was significantly more effective than Taxol in inhibiting the
tumor growth (p<0.05). Increasing the PTX dosage was associated with a further
enhancement in antitumor activity. At the PTX dosage of 20 and 40 mg/kg, the tumor
growth inhibition rate (IR) was 60.6 and 69.7%, respectively (Fig. 11B). All of the
treatments were well tolerated except for a slight decrease of body weight (7–8%) that
occurred following consecutive injections of PEG-Fmoc/PTX at the PTX dose of 40 mg/kg
(Fig. S8). The significantly enhanced antitumor activity and the excellent safety of PEG-
Fmoc/PTX are consistent with its excellent biophysical properties and tumor-selective
delivery.
4. Conclusions
In summary, a study of Fmoc/PTX molecular interaction has led to the discovery of PEG-
Fmoc conjugate as an effective nanocarrier for PTX. This conjugate can be easily
synthesized through a simple three-step route, and it readily forms small-sized (25–30 nm)
micelles with PTX. A strong Fmoc/PTX π-π stacking interaction provides an excellent drug/
carrier compatibility with a loading capacity (~36%) that stands well among the reported
micellar formulations. PEG-Fmoc/PTX nanomicelles effectively and selectively
accumulated at solid tumors and demonstrated an excellent safety profile with a MTD
greater than 120 mg PTX/kg. Finally, PEG-Fmoc/PTX effectively inhibited the tumor
growth in a murine breast cancer model, much more effectively than Taxol. Our PEG-Fmoc
may hold promise as a simple, safe, and effective delivery system for PTX with a potential
for rapid translation into clinical study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported in part by NIH grants R21CA173887, RO1CA174305, and R01GM102989. We would
like to thank Dr. Lisa Rohan for her help in DSC study.
References
1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5:161–71.
[PubMed: 15738981]
2. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS nano. 2009; 3:16–20.
[PubMed: 19206243]
3. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to
practice. Pharmacol Rev. 2001; 53:283–318. [PubMed: 11356986]
4. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive
and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014; 66:2–25.
[PubMed: 24270007]
5. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;
7:653–64. [PubMed: 20838415]
Zhang et al. Page 11






















6. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine--challenge
and perspectives. Angew Chem Int Ed. 2009; 48:872–97.
7. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006; 6:688–701.
[PubMed: 16900224]
8. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov.
2005; 4:145–60. [PubMed: 15688077]
9. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and
tumor targeting. Nanomedicine. 2010; 6:714–29. [PubMed: 20542144]
10. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat
Biotechnol. 2006; 24:1211–7. [PubMed: 17033654]
11. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine:
therapeutic applications and developments. Clin Pharmacol Ther. 2008; 83:761–9. [PubMed:
17957183]
12. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect
in macromolecular therapeutics: a review. J Control Release. 2000; 65:271–84. [PubMed:
10699287]
13. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role
of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41:189–207.
[PubMed: 11384745]
14. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control
Release. 2001; 73:137–72. [PubMed: 11516494]
15. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery
systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004; 56:1273–89. [PubMed: 15109769]
16. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles:
preparation, characterization and application in drug delivery. J Control Release. 2005; 109:169–
88. [PubMed: 16289422]
17. Huh KM, Lee SC, Cho YW, Lee J, Jeong JH, Park K. Hydrotropic polymer micelle system for
delivery of paclitaxel. J Control Release. 2005; 101:59–68. [PubMed: 15588894]
18. Kim JY, Kim S, Pinal R, Park K. Hydrotropic polymer micelles as versatile vehicles for delivery of
poorly water-soluble drugs. J Control Release. 2011; 152:13–20. [PubMed: 21352878]
19. Yoon HY, Saravanakumar G, Heo R, Choi SH, Song IC, Han MH, et al. Hydrotropic magnetic
micelles for combined magnetic resonance imaging and cancer therapy. J Control Release. 2012;
160:692–8. [PubMed: 22543013]
20. Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by
doxorubicin-PEG-folate conjugate. J Control Release. 2004; 100:247–56. [PubMed: 15544872]
21. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J
Control Release. 2004; 96:273–83. [PubMed: 15081218]
22. Gao X, Huang Y, Makhov AM, Epperly M, Lu J, Grab S, et al. Nanoassembly of surfactants with
interfacial drug-interactive motifs as tailor-designed drug carriers. Mol Pharm. 2013; 10:187–98.
[PubMed: 23244299]
23. Zhang P, Lu J, Huang Y, Zhao W, Zhang Y, Zhang X, et al. Design and evaluation of a PEGylated
lipopeptide equipped with drug-interactive motifs as an improved drug carrier. AAPS J. 2014;
16:114–24. [PubMed: 24281690]
24. Zhang Y, Gu H, Yang Z, Xu B. Supramolecular hydrogels respond to ligand-receptor interaction. J
Am Chem Soc. 2003; 125:13680–1. [PubMed: 14599204]
25. Castelletto V, Moulton CM, Cheng G, Hamley IW, Hicks MR, Rodger A, et al. Self-assembly of
Fmoc-tetrapeptides based on the RGDS cell adhesion motif. Soft Matter. 2011; 7:11405–15.
26. Jayawarna V, Ali M, Jowitt TA, Miller AE, Saiani A, Gough JE, et al. Nanostructured hydrogels
for three-dimensional cell culture through self-assembly of fluorenylmethoxycarbonyl-dipeptides.
Adv Mater. 2006; 18:611–4.
27. Shirai K, Matsuoka M, Fukunishi K. Fluorescence quenching by intermolecular pi-pi interactions
of 2,5-bis(N,N-dialkylamino)-3,6-dicyanopyrazines. Dyes Pigments. 1999; 42:95–101.
Zhang et al. Page 12






















28. Rowinsky EK, Donehower RC. Drug-therapy - paclitaxel (taxol). New Engl J Med. 1995;
332:1004–14. [PubMed: 7885406]
29. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002; 235:179–92.
[PubMed: 11879753]
30. Bertrand N, Leroux JC. The journey of a drug-carrier in the body: an anatomo-physiological
perspective. J Control Release. 2012; 161:152–63. [PubMed: 22001607]
31. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv
Drug Deliv Rev. 2007; 59:718–28. [PubMed: 17683826]
32. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev.
2007; 59:748–58. [PubMed: 17659804]
33. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;
145:182–95. [PubMed: 20226220]
Zhang et al. Page 13























Synthetic route of PEG-Fmoc (A), and schematic representation of self-assembled PEG-
Fmoc/PTX mixed micelle based on carrier/drug intermolecular π-π stacking (B).
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Biophysical characterization of PEG-Fmoc nanomicelles. (A) Particle size distribution of
PEG-Fmoc/PTX nanomicelles at 1 mg PTX/mL in DPBS with a carrier/drug ratio of 0.75:1
(m/m) via DLS measurement; (B) TEM image of PEG-Fmoc/PTX nano-micelles with PTX
concentration at 1 mg/mL using negative staining; (C) Critical micelle concentration (CMC)
measurement of PEG-Fmoc using pyrene as a fluorescence probe.
Zhang et al. Page 15























1H-NMR spectra of PEG-Fmoc/PTX in CDCl3 and D2O. The suppressed proton signals of
Fmoc motifs and PTX in D2O indicated the self-assembly of PEG-Fmoc micelles in aqueous
solution and entrapment of PTX into the interior core of PEG-Fmoc micelles.
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DSC thermograms of PTX alone, PEG-Fmoc/PTX mixed micelles, and drug-free PEG-
Fmoc micelles.
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Fluorescence quenching study. Fluorescence intensity of PEG-Fmoc (A) at 300– 460 nm
was recorded with an excitation wavelength at 270 nm, and compared with its lipid-bearing
counterpart PEG-Fmoc-OA (B). Both PEG-Fmoc and PEG-Fmoc-OA were kept at 0.88 mM
for comparison, and all carrier/drug ratios were reported as molar ratios.
Zhang et al. Page 18























13C-NMR of carrier-mixed (A & B) and carrier-free PTX (C) in CDCl3. PTX was mixed
with PEG550-α-Fmoc-ε-t-Boc-lysine (see Supplementary data) at a drug/carrier molar ratio
of 1:10 (A) and1:3 (B), respectively. Average shift index (△) was calculated as the average
absolute value of chemical shift changes of all the six carbon atoms on the same aromatic
ring compared with free PTX (C).
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Size distribution of PEG-Fmoc/PTX mixed micelles with PTX concentration at 1 mg/mL
before (A) and after (B) lyophilization/reconstitution.
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PTX release kinetics of PEG-Fmoc/PTX examined via a dialysis method. PTX
concentrations in PEG-Fmoc/PTX and Taxol were kept at 1 mg/mL, and DPBS containing
0.5% (w/v) Tween 80 was utilized as release medium. PTX concentration was analyzed at 0,
1, 2, 4, 8, 24, 48 and 72 h using HPLC at 227 nm.
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In vitro cytotoxicity of PEG-Fmoc/PTX. 4T1.2 mouse breast cancer cell line (A), human
prostate cancer cell lines PC-3 (B), and DU145 (C) were treated with PEG-Fmoc/PTX,
drug-free PEG-Fmoc and Taxol for 72 h, and tumor cell inhibition was determined by MTT
assay. * P < 0.05 or ** P < 0.01 (PEG-Fmoc/PTX vs Taxol).
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Biodistribution of PEG-Fmoc/Cy5.5-PTX in tumor-bearing mouse as examined by NIR
fluorescence imaging. Mouse bearing PC-3 cancer xenograft was scanned at 0.2 h, 24 h, 48
h, 72 h, and 96 h after i.v. injection of PEG-Fmoc/Cy5.5-PTX; and ex vivo imaging of
tumors and major organs was performed 96 h after injection.
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In Vivo therapeutic efficacy of PEG-Fmoc/PTX. Groups of 5 BALB/c mice bearing 4T1.2
murine breast cancer grafts were injected with PEG-Fmoc/PTX (10, 20, or 40 mg PTX/kg
body weight), Taxol (10 mg PTX/kg body weight) and saline on days 0, 2, 4, 7, 10 and 12,
respectively. Tumor growth was monitored and plotted as relative tumor volume (A). *P <
0.05; **P < 0.01 (vs Taxol). Tumor weights were measured after excision and plotted as
average tumor weight, and tumor growth inhibition rate (IR) was calculated (B).
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Table 2
Maximum tolerated dose of PEG-Fmoc/PTX and Taxol
Formulation Does (mg PTX/kg) Mice death Weight loss (%)
Taxol 15 0/4 0.49
20 0/4 −4.96
25 1/4 −4.35
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